...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Lamotrigine augmentation in unipolar depression.
【24h】

Lamotrigine augmentation in unipolar depression.

机译：拉莫三嗪在单相抑郁症中的增强作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A significant number of patients with unipolar depression fail to achieve remission after one or a series of antidepressants. We present the results of a retrospective chart review of the efficacy and tolerability of lamotrigine as an augmentation drug in treatment-resistant unipolar depression. A previous absence of a response was defined as the clinically significant presence of depressive symptomatology after 6 weeks of treatment with an antidepressant, with at least 3 weeks at the maximum dose tolerated by the patient. The patients were rated retrospectively using the Clinical Global Impression rating scale. Seventy-six percent of the patients improved. Gender, age, basal severity of the episode and degree of previous non response were not statistically significantly associated with response to lamotrigine augmentation. Comorbidity showed a tendency to be negatively related with response to lamotrigine. Three patients abandoned the treatment with lamotrigine due to side-effects. Complaints were excessive somnolence, headache, dizziness, nausea and malaise. Data suggest that lamotrigine is a promising drug for treatment-refractory unipolar depression. Double-blind studies are necessary to confirm its use as an augmentation agent.
机译：大量的单相抑郁症患者在接受一种或一系列抗抑郁药后未能获得缓解。我们提供回顾性图表审查的结果，拉莫三嗪作为抗药性单极抑郁症的增强药物的疗效和耐受性。先前没有反应被定义为用抗抑郁药治疗6周后，抑郁症状在临床上显着存在，并且患者可耐受的最大剂量至少3周。使用临床总体印象评分量表对患者进行回顾性评分。 76％的患者好转。性别，年龄，发作的基础严重程度和以前的无反应程度与拉莫三嗪增强反应在统计学上无显着相关性。合并症与拉莫三嗪的反应呈负相关。三名患者由于副作用而放弃使用拉莫三嗪治疗。投诉多为嗜睡，头痛，头晕，恶心和不适。数据表明，拉莫三嗪是治疗难治性单极抑郁症的有前途的药物。必须进行双盲研究以确认其用作增强剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号